week 6 tirzepatide MY UPDATE ON MOUNJARO; TIRZEPATIDE; HOW MUCH DID I LOSE, SIDE EFFECTS, BENEFITS, AND MORE Compounded Tirzepatide: My 6 Month
Description
Great Experience

First-month loss averages 5-10 pounds, though this includes water weight and glycogen depletion

To identify beneficiaries with peripheral arterial disease (PAD), we used ICD-9 diagnosis codes for PAD identified by either Hirsh et al (August 2008) or Jaff et al (July 2010) in their analyses of peripheral arterial disease among Medicare beneficiaries
However, compounded semaglutide, like all compounded drugs, is not FDA-approved and does not undergo FDA review for safety, effectiveness, or manufacturing

Patients opting for compounded versions should be aware of the variability in quality and consistency

For individuals whose diabetes was well-controlled on Mounjaro monotherapy, close blood glucose monitoring becomes essential during the treatment interruption
